Browsing by Subject "High-Throughput Screening Assays"
Now showing items 1-6 of 6
-
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
(PLoS One, 2015)Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with no effective therapeutic options. Our laboratory has previously reported the development of genetically engineered ... -
CometChip enables parallel analysis of multiple DNA repair activities.
(DNA repair, 2021-10)DNA damage can be cytotoxic and mutagenic, and it is directly linked to aging, cancer, and other diseases. To counteract the deleterious effects of DNA damage, cells have evolved highly conserved DNA repair pathways. Many ... -
Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.
(Journal of Immunological Methods, 2014-07)Luminex bead array assays are widely used for rapid biomarker quantification due to the ability to measure up to 100 unique analytes in a single well of a 96-well plate. There has been, however, no comprehensive analysis ... -
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.
(Journal of immunological methods, 2014-07)A3R5 is a human CD4(+) lymphoblastoid cell line that was engineered to express CCR5 and is useful for the detection of weak neutralizing antibody responses against tier 2 strains of HIV-1. Here we describe the optimization ... -
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.
(J Immunol Methods, 2014-07)A3R5 is a human CD4(+) lymphoblastoid cell line that was engineered to express CCR5 and is useful for the detection of weak neutralizing antibody responses against tier 2 strains of HIV-1. Here we describe the optimization ... -
Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.
(Cell Cycle, 2013-03-15)A key modality of non-surgical cancer management is DNA damaging therapy that causes DNA double-strand breaks that are preferentially toxic to rapidly dividing cancer cells. Double-strand break repair capacity is recognized ...
